Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astragalus for Cognitive Function in Mild-to-Moderate Alzheimer's Disease
NCT05578443Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of astragalus membranaceus in Alzheimer's disease (AD) (3 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 48 weeks. Started May 2024; status: recruiting.
02
Drugs
astragalus membranaceus
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05578443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578443.